ATryn

On February 6, 2009, ATryn was approved by the U.S. Food and Drug Administration (FDA) for treatment of patients with hereditary antithrombin deficiency who are undergoing surgical or childbirth procedures. Along with the approval from the FDA's pharmaceutical regulatory board, the Center for Veterinary Medicine of the FDA also approved the genetic makeup of the goats that are used to manufacture ATryn. rEVO has the sole rights to sell ATryn in the United States, and the drug is available in the U.S. market. Earlier in 2006, the European Medicines Agency (EMA) initially rejected and, after an appeal from GTC, approved the drug for use in the European Union countries.

According to Tom Newberry, the spokesperson for GTC, the company plans to acquire additional approval for treatment of those with non-hereditary antithrombin deficiency.

The Humane Society of the United States has said of the process used to manufacture ATryn, "It is a mechanistic use of animals that seems to perpetuate the notion of their being merely tools for human use rather than sentient creatures." However, the genetic changes have no known ill-effects on the host animal.